FDA approves Roche’s Xofluza to prevent flu spreading in familiesThe FDA has approved a new use for Xofluza (baloxavir marboxil) from Roche’s Genentech unit, to prevent people Share XFDA approves Roche’s Xofluza to prevent flu spreading in familieshttps://pharmaphorum.com/news/fda-approves-roches-xofluza-to-prevent-flu-spreading-in-families/
OPEN Health Group promotes Rob Barker as CEORob Barker has been promoted to chief executive officer of Marlow, UK-based OPEN Health Group after serving as Share XOPEN Health Group promotes Rob Barker as CEOhttps://pharmaphorum.com/news/open-health-group-promotes-rob-barker-ceo/
GCI London bolsters leadership with David Berkovitch hireGCI Health’s London office has bolstered its senior leadership team with the hire of David Berkovitch, who joins Share XGCI London bolsters leadership with David Berkovitch hirehttps://pharmaphorum.com/news/gci-london-bolsters-leadership-team/
Envision acquires commercial solutions firm Two LabsScientific communications company Envision Pharma has bought Two Labs, a firm specialising in commercial solutions for the pharma Share XEnvision acquires commercial solutions firm Two Labshttps://pharmaphorum.com/news/envision-acquires-commercial-solutions-two-labs/
Fresh doubts over BMS’ merger payout as FDA delays key drug reviewHolders of a risky “bet” on three Bristol-Myers Squibb drugs are looking increasingly unlikely to get their pay-out Share XFresh doubts over BMS’ merger payout as FDA delays key drug reviewhttps://pharmaphorum.com/news/fresh-doubts-over-bms-merger-payout-as-fda-delays-key-drug-review/
Divided Congress paves way for drug price reforms on Biden’s watchUnless president Donald Trump is successful with legal challenges, Democratic rival Joe Biden looks to have won the Share XDivided Congress paves way for drug price reforms on Biden’s watchhttps://pharmaphorum.com/news/biden-faces-uphill-struggle-with-health-reforms-with-divided-congress/
Could an FDA inspection scupper CVR deadline for BMS’ liso-cel?Bristol-Myers Squibb posted a solid set of financial results for the third quarter, but shares slid on investor Share XCould an FDA inspection scupper CVR deadline for BMS’ liso-cel?https://pharmaphorum.com/news/could-an-fda-inspection-scupper-cvr-deadline-for-bms-liso-cel/
Lundbeck tops Q3 expectations following strong sales of mental health drugsDenmark’s Lundbeck has beat its expectations in third quarter results, following a strong performance from its portfolio of Share XLundbeck tops Q3 expectations following strong sales of mental health drugshttps://pharmaphorum.com/news/lundbeck-tops-q3-expectations-following-strong-sales-of-mental-health-drugs/
FTC clears Mylan merger with Pfizer’s Upjohn – with conditionsMylan’s $12 billion takeover of Pfizer’s Upjohn unit has been cleared by the US authorities, but on the Share XFTC clears Mylan merger with Pfizer’s Upjohn – with conditionshttps://pharmaphorum.com/news/ftc-clears-mylan-merger-with-pfizers-upjohn-with-conditions/
Moderna banks $1.1bn in COVID-19 vaccine deposits, signs Japan supply dealModerna is still preparing for the launch of its COVID-19 vaccine mRNA-1273 – assuming phase 3 trials go Share XModerna banks $1.1bn in COVID-19 vaccine deposits, signs Japan supply dealhttps://pharmaphorum.com/news/moderna-banks-1-1bn-in-covid-19-vaccine-deposits-signs-japan-supply-deal/
Gilead Q3 revenue rise bolstered by $873m Veklury salesGilead Sciences is the first and so far only company to claim FDA approval for a COVID-19 treatment Share XGilead Q3 revenue rise bolstered by $873m Veklury saleshttps://pharmaphorum.com/news/gilead-q3-revenue-rise-bolstered-by-873m-veklury-sales/
Vaccine sales recover at GSK in Q3, but lockdown fears weigh on sharesGlaxoSmithKline saw a recovery in its vaccine sales in the third quarter after a big hit in the Share XVaccine sales recover at GSK in Q3, but lockdown fears weigh on shareshttps://pharmaphorum.com/news/vaccine-sales-recover-at-gsk-in-q3-but-lockdown-fears-weigh-on-shares/
Novartis CEO thinks 2nd health lockdown unlikely, as Q3 sales stabiliseNovartis’ pharmaceutical sales recovered in the third quarter of this year after an earlier COVID-19 decline, as new Share XNovartis CEO thinks 2nd health lockdown unlikely, as Q3 sales stabilisehttps://pharmaphorum.com/news/novartis-ceo-thinks-2nd-health-lockdown-unlikely-as-q3-sales-stabilise/
Purdue to pay $8.3bn after admitting criminal charges in opioid caseAfter years of legal wrangling, Purdue Pharma has agreed a deal to resolve litigation about its role in Share XPurdue to pay $8.3bn after admitting criminal charges in opioid casehttps://pharmaphorum.com/news/purdue-to-pay-8-3bn-after-admitting-criminal-charges-in-opioid-case/
FDA grants full approval for Roche/AbbVie’s Venclexta in AML combination therapiesCombination therapies involving Roche and AbbVie’s cancer drug Venclexta have been formally approved by the FDA in acute Share XFDA grants full approval for Roche/AbbVie’s Venclexta in AML combination therapieshttps://pharmaphorum.com/news/fda-grants-full-approval-for-roche-abbvies-venclexta-in-aml-combination-therapies/
COVID-19 tests prop up Roche as US biosimilars bite in Q3Roche’s pharmaceutical revenues have been hit by falling sales in its pharma division in Q3 but a spike Share XCOVID-19 tests prop up Roche as US biosimilars bite in Q3https://pharmaphorum.com/news/us-biosimilars-bite-into-roches-pharma-revenues/
Harmony’s sleep disorder drug Wakix gets US label extensionHarmony Biosciences has scored an expanded use for its Wakix narcolepsy drug to include cataplexy – a symptom Share XHarmony’s sleep disorder drug Wakix gets US label extensionhttps://pharmaphorum.com/news/harmonys-narcolepsy-drug-gets-extended-cataplexy/
J&J settles 1,000 talc lawsuits for $100m+; reportJohnson & Johnson has agreed to pay more than $100 million to settle over 1,000 lawsuits that allege Share XJ&J settles 1,000 talc lawsuits for $100m+; reporthttps://pharmaphorum.com/news/j-report/
